Please ensure Javascript is enabled for purposes of website accessibility

Why ImmunoGen Jumped Today

By Keith Speights - Updated Apr 15, 2019 at 12:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Anticipation of a big presentation later this week appeared to generate excitement about this clinical-stage biotech.

What happened

Shares of ImmunoGen (IMGN 2.44%) jumped 10.5% as of the market close on Monday. And the big story of the day for the biotech was... nada. ImmunoGen didn't make any announcements about its pipeline candidates. It didn't make any announcements at all. So why did the stock spike?

Perhaps the most likely reason behind ImmunoGen's big move is a "halo effect" from the J.P. Morgan Healthcare Conference. ImmunoGen isn't scheduled to present at the conference until Wednesday. However, the annual conference kicked off on Monday with lots of biotechs presenting. It isn't unusual for small biotech stocks to enjoy a nice bump from the attention they receive at the healthcare industry's biggest event of the year.

Hands holding test tubes and another hand holding a white cell phone with a purple question mark displayed on it

Image source: Getty Images.

So what

As you might expect, a sizable jump for a stock on no real news isn't anything to hang your hat on. That's especially the case for a highly volatile stock like ImmunoGen.

On the other hand, it's entirely possible that ImmunoGen provides new information at the J.P. Morgan Healthcare Conference that does give investors a reason to be positive about its prospects. Companies like to put their best foot forward at the conference.

ImmunoGen could use some good news after announcing in October that its CFO resigned. The company also reported results in October from a study of mirvetuximab soravtansine in combination with Merck's Keytruda in treating ovarian cancer that disappointed investors.

Now what

Wait 'til Wednesday. That's investors' best approach with ImmunoGen. We'll find out then if the biotech provides information that changes the investing premise for the stock either positively or negatively. 

Assuming there isn't any major announcement, though, the key things to watch with ImmunoGen are its pipeline updates that are on the way. The company expects to report initial data in mid-2019 from its Forward II study cohort evaluating a triple combo of mirvetuximab plus chemotherapies carboplatin and Roche's Avastin. It also anticipates announcing top-line results from the phase 3 Forward I study of mirvetuximab soravtansine in the first half of this year. 

Check out the latest ImmunoGen earnings call transcript.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
$4.61 (2.44%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.